ImmunoGen, Inc. Announces Clinical Presentations at the ASCO 2011 Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--May 26, 2011 - ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds – IMGN901 and SAR3419 – are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.
“Our TAP technology has an unmatched level of reported clinical data, and this body of data will expand meaningfully at ASCO this year,” said Daniel Junius, President and CEO. “On June 4th, the first clinical data for SAR3419 dosed weekly will be reported. We believe these data will provide insight into Sanofi's interest in advancing SAR3419 into Phase II testing later this year. Then, on June 5th, there will be an oral presentation featuring interim findings with our IMGN901 compound used in a combination regimen to treat multiple myeloma. The tolerability profile of IMGN901, and other TAP compounds, supports assessment as part of combination regimens, which we believe is an important development path for IMGN901.”
Saturday, June 4 – SAR3419 poster presentation with oral discussion
“Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).” (abstract #8017):
- Poster presentation: 8:00 am-12:00 noon CT, room E450b, Poster 3
- Oral discussion session: 12:00 noon-1:00 pm CT, room E354a
SAR3419 is a potential new targeted therapeutic for the treatment of B-cell NHL. It was developed initially by the Company and licensed to Sanofi from ImmunoGen's preclinical pipeline as part of a broader collaboration.
Sunday, June 5 – IMGN901 oral presentation
“Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).”(abstract #8013):
- Oral presentation: 11:30-11:45 am CT, room E354a
IMGN901 was developed by ImmunoGen and is wholly owned by the Company. It is a potential new targeted therapeutic for the treatment of small-cell lung cancer, Merkel cell carcinoma, ovarian cancer, multiple myeloma and other CD56-expressing cancers.
Other presentations at ASCO on compounds in development using ImmunoGen's TAP technology include two poster presentations in the Trials in Progress Poster session related to the design of the MARIANNE and EMILIA trastuzumab emtansine (T-DM1) Phase III clinical trials (abstracts #TPS102 and #TPS116, respectively). Trials in Progress abstracts and presentations are prohibited from including clinical findings.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently six TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Genentech (a member of the Roche Group), Novartis, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN901 and SAR3419, including risks related to uncertainties around preclinical studies, regulatory submissions and reviews, and their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2010 and other reports filed with the Securities and Exchange Commission.
Contact: ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Posted: May 2011